GFAP as a Biomarker for Alzheimer's Disease
Author Information
Author(s): Leipp Florine, Vialaret Jérôme, Mohaupt Pablo, Coppens Salomé, Jaffuel Aurore, Niehoff Ann-Christin, Lehmann Sylvain, Hirtz Christophe
Primary Institution: IRMB-PPC, INM, Univ Montpellier, CHU Montpellier, INSERM CNRS, Montpellier, France
Hypothesis
Can glial fibrillary acidic protein (GFAP) serve as a reliable biomarker for early diagnosis and monitoring of Alzheimer's disease?
Conclusion
GFAP is a promising blood-based biomarker for Alzheimer's disease, showing superior diagnostic accuracy compared to traditional CSF biomarkers.
Supporting Evidence
- GFAP levels in blood can differentiate Alzheimer's disease from other neurodegenerative disorders.
- Plasma GFAP has shown superior diagnostic accuracy compared to CSF GFAP.
- Elevated GFAP levels correlate with cognitive impairment severity in Alzheimer's disease.
- GFAP is linked to astrogliosis, which is a key feature in Alzheimer's disease pathology.
- Combining GFAP with other biomarkers improves diagnostic accuracy for Alzheimer's disease.
Takeaway
GFAP is a protein that can help doctors tell if someone has Alzheimer's disease by looking at their blood, making it easier and less painful than other tests.
Methodology
This review synthesizes existing research on GFAP as a biomarker for Alzheimer's disease, focusing on its diagnostic potential and clinical relevance.
Potential Biases
Potential publication bias in the studies reviewed may affect the conclusions drawn.
Limitations
The review is based on existing studies, which may have varying methodologies and sample sizes.
Participant Demographics
The studies included a diverse range of participants with various neurological conditions.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website